Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
References (29)
- et al.
Preliminary analysis of the Concorde trial
Lancet
(1993) - et al.
Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes
J Immunol Methods
(1992) - et al.
Simultaneous quantification of zidovudine and its metabolites in serum and urine by high-performance liquid chromatography using a column-switching technique
J Chromatog
(1990) - et al.
Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic participants with hemophilia
Blood
(1991) - et al.
The efficacy of azidothymidine (AZT) in the treatment of participants with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial
N Engl J Med
(1987) - et al.
Zidovudine in asymptomatic human immunodeficiency virus infection
N Engl J Med
(1990) - et al.
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection
Ann Intern Med
(1990) Clinical trials: a practical approach
(1988)- et al.
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection
N Engl J Med
(1992) - et al.
The effects of indomethacin and naproxen on zidovudine pharmacokinetics
Br J Clin Pharmacol
(1993)
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
MMWR
Design and analysis of randomized clinical trials requiring prolonged observation of each participant, I: introduction and design
Br J Cancer
Design and analysis of randomised clinical trials requiring prolonged observation of each participant, II: analysis and examples
Br J Cancer
Regression models and life tables
J R Statist Soc Ser B
Cited by (535)
Impact of Small-N Studies During a Pandemic
2020, ChestClinical studies of the effectiveness and safety of antivenoms
2018, ToxiconCitation Excerpt :Such a delay might pose minimal risk while providing the unique opportunity to explore the early correction of coagulopathy that has been observed and documented by many clinicians but has been questioned by some critics of antivenom therapy because of the lack of placebo control (Maduwage et al., 2015). An immediate versus deferred treatment protocol was employed in the “Concorde” trial, one of the landmark studies of anti-retroviral therapy (Concorde Coordinating Committee, 1994). In any placebo-controlled trial, early warning of unexpected morbidity in either treatment group can be provided by adopting a restricted sequential design (Armitage, 1975).
An update on oxidative stress-mediated organ pathophysiology
2013, Food and Chemical ToxicologyCitation Excerpt :Human immunodeficiency virus (HIV) (nucleoside reverse transcriptase), a fundamental cause of AIDS, is inhibited by this drug as it prevents DNA synthesis from viral RNA and attenuates viral replication (Fischl et al., 1987; Richman et al., 1987; Yarchoan et al., 1991). In 1990, besides AIDS patients, it was suggested that healthy HIV antibody-positive persons should take this drug to prevent AIDS (Volberding et al., 1990; Tokars et al., 1993; Seligmann et al., 1994) at a dose that inhibits the DNA synthesis in the HIV virus without affecting the DNA of normal host cells (Yarchoan et al., 1991). In “Highly Active Antiretroviral Therapy” chronic administration of AZT has been recommended in combination with other antiretroviral drugs (lamivudine, didanosine, etc.) (Broder, 2010).
WHO and the Evolving AIDS Pandemic
2023, Dispatches from the AIDS Pandemic: A Public Health StoryIncreased Understanding, Improved Outcomes
2023, Dispatches from the AIDS Pandemic: A Public Health StoryThe medical management of AIDS in adolescents
2022, AIDS and Adolescents
- 1
Coordinating Committee: M Seligmann and D A Warrell (joint chairmen), J-P Aboulker, C Carbon, J H Darbyshire, J Dormont, E Eschwege, D J Girling (until 1989), D R James (until 1989), J-P Levy, T E A Peto, D Schwarz, A B Stone, I V D Weller, R Withnall (secretary); K Gelmon (until 1989), E Lafon, A M Swart (trial physicians); the late V R Aber, A G Babiker, S Lhoro, A J Nunn (until 1989), M Vray (statisticians). Other committees, trials centre staff, and participating centres are listed at the end of the report. Correspondence to: Dr J H Darbyshire, MRC HIV Clinical Trials Centre, Department of Clinical Epidemiology, National Heart & Lung Institute, Royal Brompton National Heart and Lung Hospital, Sydney Street, London SW3 6NP, UK, and Dr J-P Aboulker, INSERM SC10, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif, France